High-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2023 Jun 26

PMID 37359939

Authors

Praveen Kammar

Niharika Garach

Aditi Bhatt

Jay Anam

Vashisth Maniar

Adwaita Gore

Sanket Mehta

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor performance status, or progression on systemic chemotherapy.

Methods: A retrospective analysis of patients undergoing CRS + HIPEC for peritoneal mesothelioma and receiving OMCT for poor risk factors.

Results: Sixteen patients underwent CRS + HIPEC between 2013 and 2017. The median PCI was 31.5. Complete cytoreduction (CC-0/1) was obtained in 8 patients (50%). All 16 received HIPEC except one patient with baseline renal dysfunction.Thirteen patients had PCI > 20 where only 5 had CC-0/1. Of 8 suboptimal cytoreduction (CC-2/3), 7 received OMCT (6 for progression on chemotherapy and one for mixed histology). Three patients had PCI < 20 and all had CC-0/1 clearance. Only one received OMCT for progression on adjuvant chemotherapy. Patients receiving OMCT for progression on adjuvant chemotherapy (ACT) were in poor PS.The median follow-up was 13.4 months. Five are alive with the disease (three are on OMCT). Six are alive without disease (2 are on OMCT). The mean OS was 24.3 months and the mean DFS was 18 months. Outcomes were similar between CC-0/1 and CC-2/3 groups, OMCT vs no OMCT groups.All patients receiving OMCT for progression on neoadjuvant chemotherapy had better survival (alive at 12, 20, 32, 36 months) compared to those receiving OMCT for progression on the ACT ( = 0.012).

Conclusion: OMCT is a good alternative in high-volume peritoneal mesothelioma with incomplete cytoreduction and progression on chemotherapy. OMCT may improve outcomes in these scenarios when started early.

References

Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R . Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006; 6:225. PMC: 1579231. DOI: 10.1186/1471-2407-6-225. View

Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H . EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax. 2007; 63(4):345-51. DOI: 10.1136/thx.2007.085241. View

Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S . The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20(4):1093-100. DOI: 10.1245/s10434-012-2845-x. View

Demirag F, Unsal E, Yilmaz A, Caglar A . Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005; 128(5):3382-7. DOI: 10.1378/chest.128.5.3382. View

Edwards J, Swinson D, Jones J, Muller S, Waller D, OByrne K . Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest. 2003; 124(5):1916-23. DOI: 10.1378/chest.124.5.1916. View

Garcia-Carbonero R, Paz-Ares L . Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006; 32(6):676-81. DOI: 10.1016/j.ejso.2006.03.009. View

Holtz D, Krafty R, Mohamed-Hadley A, Zhang L, Alagkiozidis I, Leiby B . Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med. 2008; 6:2. PMC: 2235830. DOI: 10.1186/1479-5876-6-2. View

Acherman Y, Welch L, Bromley C, Sugarbaker P . Clinical presentation of peritoneal mesothelioma. Tumori. 2003; 89(3):269-73. DOI: 10.1177/030089160308900307. View

Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gulla N . Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008; 18(4):426-8. DOI: 10.1097/SLE.0b013e318173a61e. View

10.

Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G . Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2005; 17(2):232-8. DOI: 10.1093/annonc/mdj066. View

11.

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G . Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193(4):468-75. DOI: 10.1002/path.824. View

12.

Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard A, Isaac S, Gilly F . Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006; 13(3):405-12. DOI: 10.1245/ASO.2006.05.041. View

13.

de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouche O . Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?. Case Rep Gastroenterol. 2012; 6(1):166-70. PMC: 3364082. DOI: 10.1159/000338070. View

14.

Simon G, Verschraegen C, Janne P, Langer C, Dowlati A, Gadgeel S . Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008; 26(21):3567-72. DOI: 10.1200/JCO.2007.15.2868. View

15.

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel R . Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol. 2013; 6(5):511-9. PMC: 3799193. DOI: 10.1593/tlo.13481. View

16.

Hubner M, Farinha H, Grass F, Wolfer A, Mathevet P, Hahnloser D . Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study. Gastroenterol Res Pract. 2017; 2017:6852749. PMC: 5346367. DOI: 10.1155/2017/6852749. View

17.

Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D . Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016; 65:69-79. DOI: 10.1016/j.ejca.2016.06.002. View

18.

Facchiano E, Scaringi S, Kianmanesh R, Sabate J, Castel B, Flamant Y . Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2007; 34(2):154-8. DOI: 10.1016/j.ejso.2007.05.015. View

19.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

20.

Odendahl K, Solass W, Demtroder C, Giger-Pabst U, Zieren J, Tempfer C . Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015; 41(10):1379-85. DOI: 10.1016/j.ejso.2015.06.001. View